Clinical trial
S0008: Chemotherapy Plus Biological Therapy in Treating Patients With Melanoma
NCT00006237 · SWOG Cancer Research Network, Other · Completed
Key facts
| NCT number | NCT00006237 |
|---|---|
| Title | S0008: Chemotherapy Plus Biological Therapy in Treating Patients With Melanoma |
| Official title | Phase III Trial of High Dose Interferon Alfa 2-b Versus Cisplatin, Vinblastine, DTIC Plus IL-2 and Interferon in Patients With High Risk Melanoma |
| Lead sponsor | SWOG Cancer Research Network, Other |
| Collaborators | National Cancer Institute (NCI) NIH Eastern Cooperative Oncology Group Cancer and Leukemia Group B Children's Oncology Group |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Melanoma (Skin) |
| Intervention type | Biological, Drug |
| Interventions | interleukin-2, filgrastim, interferon alfa, cisplatin, dacarbazine, vinblastine |
| Enrollment | 432 |
| Start date | Aug 1, 2000 |
| Primary completion | Jul 1, 2012 |
| Completion | Jul 1, 2012 |
| First posted | Jan 27, 2003 |
| Last update posted | Mar 25, 2015 |
| Countries | Australia, United States |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: